The Synovial Sarcoma SS18 Test is a specialized diagnostic tool used for the detection of specific genetic abnormalities associated with synovial sarcoma, a rare type of cancer that usually occurs near the joints of the arm, neck, or leg but can appear in any part of the body. This test focuses on identifying the SS18-SSX fusion gene, a hallmark of synovial sarcoma, which results from the translocation between chromosome X and chromosome 18. Accurate detection of this genetic marker is crucial for confirming the diagnosis of synovial sarcoma, guiding treatment decisions, and assessing prognosis.
Performed at DNA Labs UAE, a leading facility known for its advanced genetic testing capabilities, the Synovial Sarcoma SS18 Test offers patients and healthcare providers a reliable resource for diagnosing this rare cancer. The test is priced at 1800 AED, reflecting the specialized nature of the analysis and the sophisticated technology employed. By choosing DNA Labs UAE for this critical test, patients can expect high-quality diagnostic services, aiding in the effective management of synovial sarcoma through tailored treatment approaches.
Targeted Mutation Analysis 1 Mutation Test, available at DNA Labs UAE, is a specialized genetic testing process priced at 1800 AED. This test is designed to identify specific mutations within an individual's DNA, providing critical insights into genetic disorders or the risk of developing certain diseases. By focusing on a particular mutation, the test offers precise information that can aid in the diagnosis, treatment planning, or risk assessment for genetic conditions. Conducted in the state-of-the-art facilities of DNA Labs UAE, this test represents a crucial tool for individuals seeking to understand their genetic health profile concerning specific genetic mutations.
The BCR-ABL Major Quantitative Test is a crucial diagnostic and monitoring tool used in the management of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). This test specifically measures the amount of BCR-ABL fusion gene transcript in the blood or bone marrow. The presence of this gene results from a chromosomal abnormality known as the Philadelphia chromosome, which is a hallmark of CML and can also be present in ALL patients.
The test employs quantitative real-time PCR technology, allowing for the precise quantification of BCR-ABL gene transcripts. This level of precision is vital for assessing the disease's progression, evaluating patient response to therapy, and detecting minimal residual disease that may indicate a relapse.
At DNA Labs UAE, the BCR-ABL Major Quantitative Test is offered at a cost of 1800 AED. DNA Labs UAE is equipped with state-of-the-art facilities and employs highly skilled professionals to ensure the accuracy and reliability of test results. This test is a key component in the personalized treatment plans for leukemia patients, enabling healthcare providers to tailor therapies based on the genetic profile of the individual's disease and monitor their response over time.
Immunophenotyping by Flow Cytometry is a critical diagnostic tool used in the identification and classification of leukemia, a group of blood cancers that originate in the bone marrow. The "Leukemia Diagnostic Panel Customized Any 10 Markers Test" is a specialized test offered by DNA Labs UAE, designed to provide a comprehensive analysis of a patient's blood or bone marrow sample by evaluating any 10 specific markers chosen based on the individual's clinical presentation and suspected type of leukemia.
This test employs flow cytometry, a technology that enables the detailed characterization of cells based on their physical and chemical properties. By using antibodies tagged with fluorescent dyes that bind to specific antigens on the surface of the cells, flow cytometry can distinguish between different cell types and identify abnormal populations, which is crucial for diagnosing leukemia.
The selection of markers is tailored to each patient, allowing for a highly personalized assessment that can inform treatment decisions and prognosis. The test cost is set at 2190 AED, reflecting the advanced technology and expertise required to perform this sophisticated analysis.
Conducted at DNA Labs UAE, a facility known for its state-of-the-art diagnostic services, this test is part of a comprehensive approach to leukemia diagnosis, ensuring that patients receive accurate, timely, and personalized diagnostic information. This is essential for initiating the most effective treatment plans and improving patient outcomes in the battle against leukemia.
The "Immunophenotyping by Flow Cytometry Leukemia Monitoring Panel-Hairy Cell Test" is a sophisticated diagnostic procedure used to identify and monitor hairy cell leukemia, a rare type of blood cancer. This test is conducted using flow cytometry, a technology that allows for the detailed analysis of the physical and chemical characteristics of cells in a fluid as they pass through a laser. Immunophenotyping specifically examines the types of proteins or markers found on the surface of cells, which can be crucial for diagnosing different forms of leukemia, including hairy cell leukemia.
This test is invaluable for healthcare professionals as it helps in confirming the diagnosis, determining the stage of the disease, and monitoring the patient's response to treatment. By identifying the unique immunophenotypic profile of the leukemia cells, doctors can tailor treatment plans to the specific needs of the patient, improving outcomes.
The test is available at DNA Labs UAE, a leading diagnostic center known for its state-of-the-art facilities and commitment to providing accurate and timely medical results. The cost of the test is 2180 AED, which reflects the intricate technology and expertise required to perform this advanced diagnostic procedure. Patients undergoing this test at DNA Labs UAE can expect a high standard of service and reliable results that are crucial for the effective management of hairy cell leukemia.
The HLA Cadaveric Crossmatch Test is a critical diagnostic procedure conducted to ensure compatibility between a donor's organ and a recipient's immune system before organ transplantation. This test focuses on the human leukocyte antigen (HLA) system, a group of genes that play a crucial role in the body's immune response. By evaluating the interaction between the recipient's serum and the donor's HLA, the test aims to predict the likelihood of the recipient's immune system rejecting the transplanted organ.
Performed at DNA Labs UAE, a facility known for its advanced diagnostic services and state-of-the-art technology, the HLA Cadaveric Crossmatch Test is a key step in the pre-transplantation process. Ensuring compatibility can significantly increase the success rate of organ transplants and improve the recipient's prognosis.
The cost of the HLA Cadaveric Crossmatch Test at DNA Labs UAE is 2,180 AED. This price reflects the complex nature of the test and the sophisticated equipment and expertise required to accurately analyze HLA compatibility. For patients and their families, investing in this test is a critical part of the journey towards a successful organ transplant, offering hope and a chance for a healthier future.
The "Achondroplasia Mutation Analysis FGFR3 Gene G1138A G1138C Test" is a specialized genetic test designed to detect specific mutations within the FGFR3 gene, known to be the primary cause of achondroplasia. Achondroplasia is the most common form of dwarfism, characterized by a particular type of short stature, disproportionately short limbs, and other skeletal abnormalities. The mutations of interest, G1138A and G1138C, occur in the FGFR3 gene and are pivotal in diagnosing this genetic condition accurately.
This test involves analyzing the patient's DNA to identify the presence of the G1138A or G1138C mutations in the FGFR3 gene. Early and precise detection of these mutations can aid in the diagnosis, management, and understanding of the condition, facilitating personalized care and interventions for individuals with achondroplasia.
Conducted at DNA Labs UAE, a facility known for its advanced genetic testing capabilities, the test is priced at 550 AED. This cost includes the comprehensive analysis required to identify the specific mutations, providing invaluable information for affected individuals and their families. DNA Labs UAE employs state-of-the-art technology and adheres to stringent quality standards to ensure accurate and reliable test results.
The BCL2IGH t(14;18) test is a specialized diagnostic procedure designed to detect the presence of a specific chromosomal translocation between chromosomes 14 and 18, commonly referred to as t(14;18). This translocation results in the juxtaposition of the BCL2 gene on chromosome 18 next to the immunoglobulin heavy chain locus (IGH) on chromosome 14. The consequence of this genetic rearrangement is the overexpression of the BCL2 protein, which plays a crucial role in regulating cell death and is associated with the development of certain types of cancers, most notably follicular lymphoma.
The test employs sophisticated molecular biology techniques to identify the BCL2-IGH fusion gene, providing crucial information for the diagnosis, prognosis, and management of patients with suspected or confirmed lymphomas. It is particularly valuable in the clinical setting for its role in guiding treatment decisions and monitoring disease progression or response to therapy.
Conducted at DNA Labs UAE, a reputable facility known for its advanced diagnostic services, the BCL2IGH t(14;18) test is available for a cost of 1800 AED. The lab utilizes state-of-the-art technology and follows stringent quality control measures to ensure accurate and reliable results. Patients and healthcare providers considering this test can expect professionalism and confidentiality, along with comprehensive support throughout the testing process.
The BCL6 test is a diagnostic examination aimed at detecting the presence of the BCL6 gene rearrangement, which is often associated with certain types of lymphomas, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. This test is crucial for the accurate diagnosis and management of these conditions, helping healthcare professionals to tailor treatment strategies according to the genetic makeup of the tumor.
Performed at DNA Labs UAE, a leading facility known for its comprehensive genetic testing services, the BCL6 test involves the analysis of a patient's DNA to identify mutations or alterations in the BCL6 gene. This gene plays a critical role in the development and function of B cells, which are a type of white blood cell. Abnormalities in the BCL6 gene can lead to uncontrolled cell growth, contributing to the development of lymphoma.
The cost of the BCL6 test at DNA Labs UAE is 1800 AED. This investment in health allows patients and their healthcare providers to access vital genetic information that can significantly influence treatment decisions and outcomes. By identifying the genetic alterations early, patients can receive more personalized and effective therapies, improving their chances of a better health outcome.
The BCR-ABL Variant Panel is a specialized genetic test aimed at detecting specific mutations within the BCR-ABL gene. This gene is most commonly associated with chronic myeloid leukemia (CML) and, to a lesser extent, acute lymphoblastic leukemia (ALL). The test specifically looks for the Mbcr-b2a2 (e13a2), b3a2 (e14a2), and b2a3 variants, which are indicative of the presence of the Philadelphia chromosome, a genetic abnormality found in the majority of CML cases and a portion of ALL cases.
The presence of these mutations is a critical factor in diagnosing these types of leukemia and plays a significant role in determining the most effective treatment plan. Targeted therapies, such as tyrosine kinase inhibitors (TKIs), have been developed to specifically target cells containing the BCR-ABL fusion protein, making the detection of these mutations particularly important for patient care.
The test cost is set at 1800 AED and is conducted at DNA Labs UAE, a facility known for its advanced genetic testing capabilities. By offering this test, DNA Labs UAE provides essential diagnostic information that can significantly impact the treatment and management of patients with CML and ALL, potentially improving patient outcomes through personalized medicine.
